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Introduction
Bladder cancer is the 11th most common malignancy 
worldwide and one of the most common cancers of the uri-
nary tract. There are two types of bladder cancer: about 75% 
is non-muscle-invasive bladder cancer (NMIBC), the re-
maining 25% is muscle-invasive bladder cancer (MIBC) [1]. 
In the Republic of Moldova, bladder cancer ranks sec-
ond after prostate cancer, according to the nosological 
structure of tumors of the urogenital system. Over 15 years, 
cancer morbidity has almost doubled. Since 2000, due to the 
implementation of new diagnostic methods, the number of 
patients detected at the early stages has increased, which al-
lows the improvement of treatment results and the quality 
of life of patients [2].
The initial treatment of all bladder tumors includes an 
accurate transurethral resection of the tumor, which is com-
monly performed by white light (WL) cystoscopy. Full re-
section of all visible tumors with the histological examina-
tion is the standard medical care that must be performed. 
However, white light cystoscopy may fail to detect flat and 
small lesions [3]. A small, flat lesion that was, in fact, a tu-
mor or carcinoma in situ (CIS) and that was missed at the 
time of primary diagnosis and surgery can result in recur-
rence [4]. These overlooked flat lesions have the chance to 
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Abstract
Background: Early diagnosis at the incipient stages of bladder tumors is one of the current issues discussed in modern urology. Although the main 
method of diagnosis remains cystoscopy, new methods of visualization and detection of bladder tumors have been proposed over the last decade. The 
purpose of the study was to determine the impact of narrow band imaging (NBI) cystoscopy in the detection of non-muscular invasive bladder tumors 
in relation to white light (WL) cystoscopy.
Material and methods: 57 patients with bladder tumor pathology were diagnosed within the Urology Clinic of Nicolae Testemitanu State University of 
Medicine and Pharmacy during February 2016 – March 2018. All patients underwent white light cystoscopy, followed by narrow band imaging cystoscopy. 
The obtained data were comparatively analyzed.
Results: Out of the total number of 57 patients diagnosed with bladder tumors, 49 (86%) patients were diagnosed via WL cystoscopy and NBI cystoscopy 
performed after WL; tumor pathology was also detected in other 8 (14%) patients. The quantitative assessment of tumor lesions revealed 102 lesions, of 
which 75 (73.5%) were determined through WL and 27 (26.5%) tumor lesions were identified by using the NBI method.
Conclusions: Narrow band imaging cystoscopy determines more favorable results in the early diagnosis of non-muscular invasive bladder tumors 
compared to white light cystoscopy.
Key words: narrow band imaging cystoscopy.
Cite this article
Vladanov I, Plesacov A, Scutelnic G, Ghicavii V. Early detection of urinary bladder tumors with narrow band imaging. Mold Med J. 2020;63(5):35-38. 
doi: 10.5281/zenodo.4018927. 
recur: about 61% in the 1st year and 78% within the 5th year, 
which may even progress into invasive bladder cancer: ap-
proximately 17% in the first year and 45% during the 5th year 
[5, 6]. Because of these great rates of recurrence and preva-
lence, bladder cancer is a large burden on the economy and 
medical insurance [7].
To optimize the therapeutic and diagnostic approach of 
NMIBC narrow band imaging (NBI) cystoscopy has been 
introduced into the medical practical use. NBI is an opti-
cal image enhancement technique that uses wavelengths in 
the blue – 415 nm and green – 540 nm zone of the electro-
magnetic spectrum. These specific wavelengths are strongly 
absorbed by hemoglobin and vascular structures, such as 
tumors and areas of carcinoma in situ, making them appear 
dark brown or green against a pink or white normal muco-
sal background, without the use of any dye [8]. NBI is use-
ful in endoscopy detection of early stages of gastrointestinal 
cancer that is, therefore, expected to play a significant role in 
the diagnosis of NMIBC [9].
The aim of the study is to determine the impact of nar-
row band imaging cystoscopy in the detection of non-mus-
cular invasive bladder tumors if compared to white light 
cystoscopy.
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Material and methods
The study was conducted on 57 patients, diagnosed 
with bladder tumor pathology within the Department of 
Urology and Surgical Nephrology of Nicolae Testemitanu 
State University of Medicine and Pharmacy, in Timofei 
Mosneaga Republican Clinical Hospital during February 
2016 – March 2018. A transversal descriptive study was 
performed. The patients were selected from all amount of 
bladder tumor patients treated in our department by cys-
toscopy with transurethral resection of the bladder tumors, 
according to the following criteria. The patients inclusion 
criteria were primary non-muscular invasive bladder can-
cer, patients aged over 18 and the Eastern Cooperative 
Oncology Group (ECOG) score 0-2. The exclusion criteria 
were identified as follows: other non-urothelial tumors, se-
vere comorbidities, ECOG score ≥ 3, and pregnancy. White 
light cystoscopy was performed in all patients, followed by 
narrow band imaging cystoscopy; the obtained data were 
comparatively analyzed. Descriptive statistics was applied. 
The results of the study are presented as absolute and rela-
tive values.
Results
The demographic data of the patients with NMIBC are 
presented in table 1.
Of the 57 patients included in the study, based on gen-
der distribution, 48 (84%) were men and 9 (16%) were 
women. The age ranged between 24-85 years old, the mean 
age was 65.4 years. The number of patients, included in the 
18- 30-year-old age group was 4 (7%), confirming that blad-
der cancer is an older age-related disease. In 17 (30%) of 
the patients included in the research, age varied from 31 to 
60 years. However, the most common study age group was 
over 60, which consisted of 36 patients (63%). Another im-
portant risk factor for the development of bladder cancer is 
tobacco smoking. 24 (42%) patients out of 57 are tobacco 
users.
Tumor analysis showed that the majority of the patient’s 
single bladder tumor was detected in 36 (63%) cases. 2 tu-
mors were discovered in 9 (16%) cases and multiple tumors 
– 3 cases and more – in 12 (21%) patients. According to 
bladder tumor volume, 49 (86%) patients included in the 
study had up to 3 cm size, and massive tumors of over 3 cm 
were recorded in 8 (14%) cases.
The results of the histopathological examination after the 
T stage showed that stage Tis was observed in 3 (5%) cases, 
stage Ta was detected in the majority of the patients that 
made up 35 (61.5%) cases and stage T1 was in 19 (33.5%) 
cases. 
According to the WHO/ISUP 2004 classification: 
PUNLMP – papillary urothelial neoplasm of low malignant 
potential was detected in 3 (5%) cases, low-grade papillary 
urothelial carcinoma – in 25 (44%) patients and high-grade 
papillary urothelial carcinoma – in 29 (51%) cases of pa-
tients included in research.
Out of the total number of 57 patients, diagnosed with 
Table 1
Patient and tumor demographics
Parameters Categories Patients (n=57)
Gender: Men, n (%) 48 (84%)
Women, n (%) 9 (16%)
Age, years Mean age (CI 95%) 65.4 (26-83)
Age group: 18-30 years, n (%) 4 (7%)
31- 60 years, n (%) 17 (30%)
60 years and more, 
n (%)
36 (63%)
Tobacco/Smoking Yes, n (%) 24 (42%)
Tumor size: < 1 cm, n (%) 22 (38.5%)
1-3 cm, n (%) 27 (47.5%)
> 3 cm, n (%) 8 (14%)
Number of tumors: Single tumors, n (%) 36 (63%)
2 tumors, n (%) 9 (16%)
> 2 tumors, n (%) 12 (21%)
T stage: Tis (CIS), n (%) 3 (5%)
Ta, n (%) 35 (61.5%)
T1, n (%) 19 (33.5%)
Histopathology 
grade:
PUNLMP, n (%) 3 (5%)
Low-grade, n (%) 25 (44%)
High-grade, n (%) 29 (51%)
Note: CI — Confidence Interval, Tis (CIS) — Carcinoma in situ, “flat 
tumor”, Ta — Noninvasive papillary tumor, T1 — Invades subepithelial 
connective tissue, PUNLMP — papillary urothelial neoplasm of low 
malignant potential, Low-grade — Low-grade papillary urothelial 
carcinoma, High-grade — High-grade papillary urothelial carcinoma.
Table 2
Detection of tumor lesions during white light  










n % n % n %
Tumor lesions 75 73.5% +27 +26.5% 102 100%
Number of 
patients 49 86% +8 +14% 57 100%
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bladder tumors (tab. 2), this diagnosis was established by 
WL cystoscopy in 49 (86%) patients, and by NBI cystoscopy 
performed after WL; the tumor pathology was detected in 8 
(14%) patients. The quantitative assessment of tumor lesions 
revealed 102 lesions, of which 75 (73.5%) were determined 
through WL and 27 (26.5%) tumor lesions were identified 
using the NBI method. Of CIS lesions, 1 lesion was detected 
during WL and other 2 with NBI.
Discussion
Despite being introduced within a urologic setting more 
than 10 years ago, NBI is still not being routinely utilized 
in the detection of NMIBC. Nevertheless, some researches 
have shown that NBI is more efficient in detecting NMIBC 
than WL. Bryan et al., who first introduced NBI in the uro-
logic setting, found that 15 additional urothelial carcinomas 
were detected in 12 of 29 patients (41%) [10].
The proposal of a new cystoscopy visualization tech-
nique, should meet at least two requirements:  first, it must 
improve the diagnostic precision in the detection of bladder 
cancer and second, the implementation of the technique in 
the transurethral treatment should be capable to decrease 
the risk of progression and/or recurrence. Different studies 
have demonstrated an improvement in the diagnostic rate of 
bladder tumors using NBI, but it remains unclear whether 
the increase of detection rate is due to the second accurate 
examination of the bladder only [11].
According to the data of the specialized literature, com-
pared to WL, NBI can detect more tumors in 9%-56% ad-
ditional patients [3, 10, 12-16]. In our study, NBI discovered 
additional pathologies in extra 14% of patients.
According to the acknowledged superiority of NBI in 
the detection of extra tumors, as well as in our research, 
NBI has revealed additional 26.5% of tumor lesions. 
However, the site of the resection with NBI control in the 
transurethral resection algorithm remains to be clearly de-
termined [17].
However, it has been observed that visibility during NBI 
was restricted due to inflammation and bleeding, making it 
hard to reveal and resect tumor lesions. It may be the case 
because wavelengths during NBI are actively absorbed by 
free hemoglobin, which occurs in bleeding [14].
In the detection of additional tumors, NBI cystoscopy is 
superior to WL cystoscopy. NBI is not perfect for the prima-
ry resection of multiple and large tumors due to poor visual-
ization. However, NBI can influence the finding of residual 
or missed tumors after initial resection under WL. It may be 
right to propose the adage “NBI to detect, WL to resect” for 
future use [18].
Conclusions
Narrow band imaging cystoscopy determines more fa-
vorable results in the early diagnosis of non-muscular-in-
vasive bladder tumors compared to white light cystoscopy. 
Only adequate equipment is required to perform the NBI 
cystoscopy. The technique is easy to apply, just pushing on a 
single button, without using additional medical substances. 
In our research, NBI was able to detect additional patholo-
gies in 8 (14%) patients and detected 27 (26.5%) additional 
tumor lesions.
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